ESR1 and breast carcinoma: Similarly, clinical trials in PIK3CA-mutant breast cancer have demonstrated that the combination of the PIK3CA-selective inhibitor alpelisib and estrogen receptor (ER) degrader fulvesterant improves radiographic progression-free survival (8).